| Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis. | |
| | |
MedLine Citation:
|
PMID: 15852403 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of the neuromuscular system resulting in paralysis and ultimately death. Currently, no effective therapy is prescribed for patients; however, several therapeutic strategies are showing promise. Either exercise or treatment with adeno-associated virus/insulin-like growth factor-1 alone has therapeutic benefits in an amyotrophic lateral sclerosis transgenic mouse model. We show here that activity duration affects the therapeutic benefit associated with exercise, with 6- and 12-hour exposure to a running wheel providing significant motor function benefits and increased survival. Remarkably, a combination of insulin-like growth factor-1 gene delivery and exercise has profound effects on survival and function, indicative of synergistic effects with exercise and insulin-like growth factor-1. Our results indicate that a drug treatment in combination with appropriate exercise may provide the most promising therapy for amyotrophic lateral sclerosis to date. |
| | |
Authors:
|
Brian K Kaspar; Lindsay M Frost; Lindsey Christian; Priya Umapathi; Fred H Gage |
Related Documents
:
|
18570643 - A randomised controlled trial evaluating family mediated exercise (fame) therapy follow... 9637933 - Exercise limitations and training for patients with cystic fibrosis. 12818463 - Lean body mass and bone mineral density in physically exercising postmenopausal women. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Annals of neurology Volume: 57 ISSN: 0364-5134 ISO Abbreviation: Ann. Neurol. Publication Date: 2005 May |
Date Detail:
|
Created Date: 2005-05-02 Completed Date: 2005-06-24 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 7707449 Medline TA: Ann Neurol Country: United States |
Other Details:
|
Languages: eng Pagination: 649-55 Citation Subset: IM |
Affiliation:
|
The Salk Institute for Biological Studies, La Jolla, CA 92037, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aging
/
physiology Amyotrophic Lateral Sclerosis / drug therapy, pathology, therapy* Animals Brain Chemistry / genetics Cell Count Dependovirus / genetics Exercise Therapy* Gene Expression Gene Therapy* Heterozygote Humans Immunohistochemistry Insulin-Like Growth Factor I / genetics* Longevity Mice Mice, Transgenic Motor Activity / physiology Plasmids / genetics Postural Balance / physiology RNA / biosynthesis, genetics Running Spinal Cord / pathology Superoxide Dismutase / genetics Survival Analysis |
| Grant Support | |
ID/Acronym/Agency:
|
AG21876/AG/NIA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
63231-63-0/RNA; 67763-96-6/Insulin-Like Growth Factor I; EC 1.15.1.-/superoxide dismutase 1; EC 1.15.1.1/Superoxide Dismutase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Transient ischemic attack with infarction: a unique syndrome?
Next Document: Is freezing of gait in Parkinson's disease related to asymmetric motor function?